The Russian cancer vaccine is ready for use, Izvestia reported, citing Veronika Skvortsova, head of the Federal Medical-Biological Agency.
Preclinical studies have confirmed the safety and efficacy of the drug. At the end of the summer, the FMBA sent documents to the Ministry of Health to obtain permission for clinical use.
As previously reported, from September 2025, the vaccine will be used to treat patients with primary melanoma, as well as those who have undergone certain stages of therapy. The drug was developed by the Gamaleya Research Center for Epidemiology and Microbiology.
Read materials on the topic:
Russian cancer vaccine has successfully passed preclinical trials
Now on home
The service contains data on 45,000 fraudulent sites
Modernized engines may equip the Lada Azimut crossover
The price is 132 billion 265.8 million rubles
The manufacturer plans to strengthen its lineup of light commercial vehicles
The production of carbon fiber was organized in the shortest possible time
Electric vans will speed up the repair of urban transport infrastructure
Countries are working to synchronize regulations in the field of AI
The service's average daily audience is 55 million people
Stable Isomaterial Based on Metakaolin Has a Density Below 300 kg/m³
Re-identification quality improved twofold with new DynaMix method
Russians will be able to find out about debts online